Aclaris Therapeutics Salute del bilancio
Salute finanziaria criteri di controllo 6/6
Aclaris Therapeutics ha un patrimonio netto totale di $130.2M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $182.4M e $52.2M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
US$0
Debito
| Indice di copertura degli interessi | n/a |
| Contanti | US$127.72m |
| Patrimonio netto | US$130.15m |
| Totale passività | US$52.24m |
| Totale attività | US$182.39m |
Aggiornamenti recenti sulla salute finanziaria
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
Aug 08
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Recent updates
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 12Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?
Aug 08We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
May 03Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 19Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 11Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results
Aug 10What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Jun 06We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
Oct 06Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata
Aug 25Aclaris Therapeutics gets a new COO
Aug 01Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
Dec 14Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( $132.3M ) di ACRS superano le sue passività a breve termine ( $18.8M ).
Passività a lungo termine: Le attività a breve termine di ACRS ( $132.3M ) superano le sue passività a lungo termine ( $33.4M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: ACRS è esente da debiti.
Riduzione del debito: ACRS non ha debiti rispetto a 5 anni fa, quando il suo rapporto debito/patrimonio netto era 35.1%.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: ACRS ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.
Previsione Cash Runway: ACRS ha una liquidità sufficiente per 2.2 anni se il flusso di cassa libero continua a crescere ai tassi storici del 8.7 % ogni anno.